AstraZeneca's blood cancer drug meets main goal in late-stage trial
AstraZeneca Plc said on Thursday its blood cancer drug met the main goal of a final stage trial, taking the treatment one step closer to a marketing approval as the drugmaker seeks to bolster its oncology portfolio.
from Reuters: Health News https://reut.rs/2K0ybHg
http://bit.ly/2zwRqiM
June 06, 2019
|
Labels:
health,
Reuters: Health News
|
This entry was posted on June 06, 2019
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.